In vitro selection of cancer cell-specific molecular recognition elements from amino acid libraries

Journal of Immunology Research

Volumn 2015, Issue , 2015, Pages

  Williams, Ryan M ^a,b   Sooter, Letha J ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTIBODY; MESSENGER RNA; MOLECULAR RECOGNITION ELEMENT; PEPTIDE; UNCLASSIFIED DRUG; APTAMER; LIGAND; PEPTIDE LIBRARY;

CANCER CELL; HOST; HUMAN; IN VITRO SELECTION; MAMMAL CELL; MOLECULAR LIBRARY; NONHUMAN; PHAGE DISPLAY; REVIEW; RIBOSOME; TARGET CELL; YEAST; ANIMAL; CELL SURFACE DISPLAY; GENETICS; IMMUNOLOGY; IN VITRO STUDY; NEOPLASM; PEPTIDE LIBRARY; SYSTEMATIC EVOLUTION OF LIGANDS BY EXPONENTIAL ENRICHMENT APTAMER TECHNIQUE;

AMINO ACIDS; ANIMALS; APTAMERS, NUCLEOTIDE; CELL SURFACE DISPLAY TECHNIQUES; HUMANS; IN VITRO TECHNIQUES; LIGANDS; NEOPLASMS; PEPTIDE LIBRARY; SELEX APTAMER TECHNIQUE;

EID: 84942284327     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2015/186586     Document Type: Review

References (127)

1. C. Tuerk and L. Gold, "Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase, " Science, vol. 249, no. 4968, pp. 505-510, 1990.
2. A. D. Ellington and J. W. Szostak, "In vitro selection of RNA molecules that bind specific ligands, " Nature, vol. 346, no. 6287, pp. 818-822, 1990.
3. R. R. Breaker and G. F. Joyce, "A DNA enzyme that cleaves RNA, " Chemistry and Biology, vol. 1, no. 4, pp. 223-229, 1994.
4. D. E. Huizenga and J. W. Szostak, "A DNA aptamer that binds adenosine and ATP, " Biochemistry, vol. 34, no. 2, pp. 656-665, 1995.
5. L. A. Gugliotti, D. L. Feldheim, andB. E. Eaton, "RNA-mediated metal-metal bond formation in the synthesis of hexagonal palladium nanoparticles, " Science, vol. 304, no. 5672, pp. 850-852, 2004.
6. L. R. Paborsky, S. N. McCurdy, L. C. Griffin, J. J. Toole, and L. L. K. Leung, "The single-stranded DNA aptamer-binding site of human thrombin, "The Journal of Biological Chemistry, vol. 268, no. 28, pp. 20808-20811, 1993.
7. E. T. Boder, K. S. Midelfort, and K. D. Wittrup, "Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 20, pp. 10701-10705, 2000.
8. M. El-Mousawi, L. Tchistiakova, L. Yurchenko et al. , "A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library, " Journal of Biological Chemistry, vol. 278, no. 47, pp. 46681-46691, 2003.
9. C. Schaffitzel, I. Berger, J. Postberg, J. Hanes, H. J. Lipps, and A. Plckthun, "In vitro generated antibodies specific for telomeric guanine-quadruplex DNA react with Stylonychia lemnae macronuclei, " Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 15, pp. 8572-8577, 2001.
10. D. Kase, J. L. Kulp III, M. Yudasaka, J. S. Evans, S. Iijima, and K. Shiba, "Affinity selection of peptide phage libraries against single-wall carbon nanohorns identifies a peptide aptamer with conformational variability, " Langmuir, vol. 20, no. 20, pp. 8939-8941, 2004.
11. K. N. Morris, K. B. Jensen, C. M. Julin, M. Weil, and L. Gold, "High affinity ligands from in vitro selection: complex targets, " Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 6, pp. 2902-2907, 1998.
12. M. Blank, T. Weinschenk, M. Priemer, and H. Schluesener, "Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels: selective targeting of endothelial regulatory protein pigpen, "The Journal of Biological Chemistry, vol. 276, no. 19, pp. 16464-16468, 2001.
13. K. Sefah, Z. W. Tang, D. H. Shangguan et al. , "Molecular recognition of acute myeloid leukemia using aptamers, " Leukemia, vol. 23, no. 2, pp. 235-244, 2009.
14. D. Shangguan, L. Meng, Z. C. Cao et al. , "Identification of liver cancer-specific aptamers using whole live cells, " Analytical Chemistry, vol. 80, no. 3, pp. 721-728, 2008.
15. Z. Zhao, L. Xu, X. Shi, W. Tan, X. Fang, and D. Shangguan, "Recognition of subtype non-small cell lung cancer by DNA aptamers selected from living cells, " Analyst, vol. 134, no. 9, pp. 1808-1814, 2009.
16. C. R. Ireson and L. R. Kelland, "Discovery and development of anticancer aptamers, "Molecular CancerTherapeutics, vol. 5, no. 12, pp. 2957-2962, 2006.
17. K.-T. Guo, G. Ziemer, A. Paul, H. P. Wendel, and H. P. Wendel, "Cell-SELEX: novel perspectives of aptamer-based therapeutics, " International Journal of Molecular Sciences, vol. 9, no. 4, pp. 668-678, 2008.
18. Y. Kim, C. Liu, andW. Tan, "Aptamers generated by cell SELEX for biomarker discovery, " Biomarkers in Medicine, vol. 3, no. 2, pp. 193-202, 2009.
19. L. Cerchia, J. Hamm, D. Libri, B. Tavitian, and V. De Franciscis, "Nucleic acid aptamers in cancer medicine, " FEBS Letters, vol. 528, no. 1-3, pp. 12-16, 2002.
20. J. F. Lee, G. M. Stovall, and A. D. Ellington, "Aptamer therapeutics advance, " Current Opinion in Chemical Biology, vol. 10, no. 3, pp. 282-289, 2006.
21. C. E. Chan, A. P. Lim, P. A. Macary, andB. J. Hanson, "The roleof phage display in therapeutic antibody discovery, " International Immunology, vol. 26, no. 12, Article ID dxu082, pp. 649-657, 2014.
22. A. Pourmir and T. W. Johannes, "Directed evolution: selection of the host organism, " Computational and Structural Biotechnology Journal, vol. 2, no. 3, Article ID e201209012, pp. 1-7, 2012.
23. L. R. Krumpe and T. Mori, "T7 lytic phage-displayed peptide libraries: construction and diversity characterization, " in Therapeutic Peptides, pp. 51-66, Springer, 2014.
24. J. W. Ellefson, A. J. Meyer, R. A. Hughes, J. R. Cannon, J. S. Brodbelt, and A. D. Ellington, "Directed evolution of genetic parts and circuits by compartmentalized partnered replication, " Nature Biotechnology, vol. 32, no. 1, pp. 97-101, 2014.
25. M. Galanis, R. A. Irving, and P. J. Hudson, "Bacteriophage library construction and selection of recombinant antibodies, " Current Protocols in Immunology, chapter 17:unit 17. 1, 1997.
26. E. T. Boder and K. D. Wittrup, "Yeast surface display for screening combinatorial polypeptide libraries, " Nature Biotechnology, vol. 15, no. 6, pp. 553-557, 1997.
27. H. Gram, L.-A. Marconi, C. F. Barbas III, T. A. Collet, R. A. Lerner, and A. S. Kang, "In vitro selection and affinity maturation of antibodies from a naive combinatorial immunoglobulin library, " Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 8, pp. 3576-3580, 1992.
28. P. S. Daugherty, G. Chen, B. L. Iverson, and G. Georgiou, "Quantitative analysis of the effect of the mutation frequency on the affinity maturation of single chain Fv antibodies, " Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 5, pp. 2029-2034, 2000.
29. Y. Georgieva and Z. Konthur, "Design and screening of M13 phage displayCdna Libraries, "Molecules, vol. 16, no. 2, pp. 1667-1681, 2011.
30. L. B. Giebel, R. T. Cass, D. L. Milligan, D. C. Young, R. Arze, and C. R. Johnson, "Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities, " Biochemistry, vol. 34, no. 47, pp. 15430-15435, 1995.
31. P. Pansri, N. Jaruseranee, K. Rangnoi, P. Kristensen, and M. Yamabhai, "A compact phage display human scFv library for selection of antibodies to a wide variety of antigens, " BMC Biotechnology, vol. 9, article 6, 2009.
32. K. Li, K. A. Zettlitz, J. Lipianskaya et al. , "A fully human scFv phage display library for rapid antibody fragment reformatting, " Protein Engineering Design and Selection, 2015.
33. W. D. Huse, L. Sastry, S. A. Iverson et al. , "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda, " Science, vol. 246, no. 4935, pp. 1275-1281, 1989.
34. J. Tanha, J. Entwistle, S. Narang, M. Dan, C. R. Mackenzie, and H. Kaplan, "Phage Display Libraries of Human Vh Fragments, " Google Patents, 2013.
35. P. Vaccaro, E. Pavoni, G. Monteriu, P. Andrea, F. Felici, and O. Minenkova, "Efficient display of scFv antibodies on bacteriophage lambda, " Journal of Immunological Methods, vol. 310, no. 1-2, pp. 149-158, 2006.
36. E. S. Smith and M. Zauderer, "Antibody library display on a mammalian virus vector: combining the advantages of both phage and yeast display into one technology, " Current Drug Discovery Technologies, vol. 11, no. 1, pp. 48-55, 2014.
37. B. K. Kay, J. Kasanov, and M. Yamabhai, "Screening phagedisplayed combinatorial peptide libraries, " Methods, vol. 24, no. 3, pp. 240-246, 2001.
38. Z. Lu, K. S. Murray, V. Van Cleave, E. R. Lavallie, M. L. Stahl, and J. M. McCoy, "Expression of thioredoxin random peptide libraries on the Escherichia coli cell surface as functional fusions to flagellin: a system designed for exploring protein-protein interactions, " Nature Biotechnology, vol. 13, no. 4, pp. 366-372, 1995.
39. P. H. Bessette, J. J. Rice, and P. S. Daugherty, "Rapid isolation of high-affinity protein binding peptides using bacterial display, " Protein Engineering, Design and Selection, vol. 17, no. 10, pp. 731-739, 2004.
40. P. S. Daugherty, G. Chen, M. J. Olsen, B. L. Iverson, and G. Georgiou, "Antibody affinity maturation using bacterial surface display, " Protein Engineering, vol. 11, no. 9, pp. 825-832, 1998.
41. E. Gunneriusson, P. Samuelson, M. Uhle, P.- A. Nygren, and S. Stahl, "Surface display of a functional single-chain Fv antibody on Staphylococci, " Journal of Bacteriology, vol. 178, no. 5, pp. 1341-1346, 1996.
42. F. Fleetwood, N. Devoogdt, M. Pellis et al. , "Surface display of a single-domain antibody library on Gram-positive bacteria, " Cellular andMolecular Life Sciences, vol. 70, no. 6, pp. 1081-1093, 2013.
43. Z. Lu, E. R. Lavallie, and J. M. Mccoy, "Using bio-panning of flitrx peptide libraries displayed on E. Coli cell surface to study protein-protein interactions, " in E. coli Gene Expression Protocols, vol. 205 ofMethods inMolecular Biology, pp. 267-280, Humana Press, 2003.
44. N. Kronqvist, J. Lfblom, A. Jonsson, H. Wernrus, and S. Stahl, "A novel affinity protein selection system based on staphylococcal cell surface display and flow cytometry, " Protein Engineering, Design and Selection, vol. 21, no. 4, pp. 247-255, 2008.
45. P. S. Daugherty, "Protein engineering with bacterial display, " CurrentOpinion in Structural Biology, vol. 17, no. 4, pp. 474-480, 2007.
46. E. M. Krauland, B. R. Peelle, K. D. Wittrup, and A. M. Belcher, "Peptide tags for enhanced cellular and protein adhesion to single-crystalline sapphire, " Biotechnology and Bioengineering, vol. 97, no. 5, pp. 1009-1020, 2007.
47. S. Bidlingmaier, Y. Su, and B. Liu, "Combining phage and yeast cell surface antibody display to identify novel cell typeselective internalizing human monoclonal antibodies, " in Yeast Surface Display: Methods, Protocols, and Applications, vol. 1319 ofMethods inMolecular Biology, pp. 51-63, Springer, NewYork, NY, USA, 2015.
48. T. Van Den Beucken, H. Pieters, M. Steukers et al. , "Affinity maturation of Fab antibody fragments by fluorescent-activated cell sorting of yeast-displayed libraries, " The FEBS Letters, vol. 546, no. 2-3, pp. 288-294, 2003.
49. H. H. Shaheen, B. Prinz, M.-T. Chen et al. , "A dual-mode surface display system for the maturation and production of monoclonal antibodies in glyco-engineered pichia pastoris, " PLoS ONE, vol. 8, no. 7, Article ID e70190, 2013.
50. M. J. Feldhaus and R. W. Siegel, "Yeast display of antibody fragments: a discovery and characterization platform, " Journal of Immunological Methods, vol. 290, no. 1-2, pp. 69-80, 2004.
51. S. Park, Y. Xu, X. F. Stowell, F. Gai, J. G. Saven, and E. T. Boder, "Limitations of yeast surface display in engineering proteins of high thermostability, " Protein Engineering, Design and Selection, vol. 19, no. 5, pp. 211-217, 2006.
52. L. Benatuil, J. M. Perez, J. Belk, and C.-M. Hsieh, "An improved yeast transformation method for the generation of very large human antibody libraries, " Protein Engineering, Design and Selection, vol. 23, no. 4, pp. 155-159, 2010.
53. X. X. Wang and E. V. Shusta, "The use of scFv-displaying yeast in mammalian cell surface selections, " Journal of Immunological Methods, vol. 304, no. 1-2, pp. 30-42, 2005.
54. G. Chao, W. L. Lau, B. J. Hackel, S. L. Sazinsky, S. M. Lippow, and K. D. Wittrup, "Isolating and engineering human antibodies using yeast surface display, " Nature Protocols, vol. 1, no. 2, pp. 755-768, 2006.
55. J. A. Van Deventer and K. D. Wittrup, "Yeast surface display for antibody isolation: library construction, library screening, and affinity maturation, " in Monoclonal Antibodies, pp. 151-181, Springer, 2014.
56. R. Wolkowicz, G. C. Jager, and G. P. Nolan, "A random peptide library fused to CCR5 for selection of mimetopes expressed on the mammalian cell surface via retroviral vectors, " Journal of Biological Chemistry, vol. 280, no. 15, pp. 15195-15201, 2005.
57. M. Ho and I. Pastan, "Display and selection of scFv antibodies on HEK-293T cells, "Methods inMolecular Biology, vol. 562, pp. 99-113, 2009.
58. V. Alonso-Camino, D. Snchez-Marti, M. Compte et al. , "CARbodies: Human antibodies against cell surface tumor antigens selected from repertoires displayed on T cell chimeric antigen receptors, " Molecular Therapy-Nucleic Acids, vol. 2, article e93, 2013.
59. R. R. Beerli, M. Bauer, R. B. Buser et al. , "Isolation of human monoclonal antibodies bymammalian cell display, " Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14336-14341, 2008.
60. C. Yu, G. M. Pike, T. A. Rinkoski, C. Correia, S. H. Kaufmann, and M. J. Federspiel, "Efficient method to optimize antibodies using avian leukosis virus display and eukaryotic cells, " Proceedings of the National Academy of Sciences of the United States of America, vol. 112, no. 32, pp. 9860-9865, 2015.
61. M. Ho and I. Pastan, "Mammalian cell display for antibody engineering, " in Therapeutic Antibodies, vol. 525 of Methods in Molecular Biology, pp. 337-352, Humana Press, 2009.
62. S. Dietmair, L. K. Nielsen, and N. E. Timmins, "Mammalian cells as biopharmaceutical production hosts in the age of omics, " Biotechnology Journal, vol. 7, no. 1, pp. 75-89, 2012.
63. J. Hanes and A. Plckthun, "In vitro selection and evolution of functional proteins by using ribosome display, " Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 10, pp. 4937-4942, 1997.
64. D. Lipovsek and A. Plckthun, "In-vitro protein evolution by ribosome display and mRNA display, " Journal of Immunological Methods, vol. 290, no. 1-2, pp. 51-67, 2004.
65. A. D. Foster, J. D. Ingram, E. K. Leitch, K. R. Lennard, E. L. Osher, and A. Tavassoli, "Methods for the creation of cyclic peptide libraries for use in lead discovery, " Journal of Biomolecular Screening, vol. 20, no. 5, pp. 563-576, 2015.
66. C. Schaffitzel, J. Hanes, L. Jermutus, and A. Plckthun, "Ribosome display: an in vitro method for selection and evolution of antibodies fromlibraries, " Journal of ImmunologicalMethods, vol. 231, no. 1-2, pp. 119-135, 1999.
67. C. Zahnd, P. Amstutz, and A. Plckthun, "Ribosome display: selecting and evolving proteins in vitro that specifically bind to a target, " Nature Methods, vol. 4, no. 3, pp. 269-279, 2007.
68. S. W. Cotten, J. Zou, C. A. Valencia, and R. Liu, "Selection of proteins with desired properties from natural proteome libraries using mRNA display, " Nature Protocols, vol. 6, no. 8, pp. 1163-1182, 2011.
69. K.-T. Guo, G. Ziemer, A. Paul, and H. P. Wendel, "Cell-selex: novel perspectives of aptamer-based therapeutics, " International Journal of Molecular Sciences, vol. 9, pp. 668-678, 2008.
70. H. W. Chen, C. D. Medley, K. Sefah et al. , "Molecular recognition of small-cell lung cancer cells using aptamers, " ChemMed-Chem, vol. 3, no. 6, pp. 991-1001, 2008.
71. B. M. Larimer and S. L. Deutscher, "Development of a peptide by phage display for SPECT imaging of resistance-susceptible breast cancer, " American Journal of Nuclear Medicine and Molecular Imaging, vol. 4, no. 5, pp. 435-447, 2014.
72. G. S. Shukla and D. N. Krag, "Phage display selection for cellspecific ligands: development of a screening procedure suitable for small tumor specimens, " Journal of Drug Targeting, vol. 13, no. 1, pp. 7-18, 2005.
73. U. B. Rasmussen, V. Schreiber, H. Schultz, F. Mischler, and K. Schughart, "Tumor cell-targeting by phage-displayed peptides, " Cancer Gene Therapy, vol. 9, no. 7, pp. 606-612, 2002.
74. A. Odermatt, A. Audig, C. Frick et al. , "Identification of receptor ligands by screening phage-display peptide libraries ex vivo on microdissected kidney tubules, " Journal of the American Society of Nephrology, vol. 12, no. 2, pp. 308-316, 2001.
75. R. M. Williams, C. J. Hajiran, S. Nayeem, and L. J. Sooter, "Identification of an antibody fragment specific for androgendependent prostate cancer cells, " BMC Biotechnology, vol. 14, article 81, 2014.
76. T. J. Sang, J. J. Ki, B. L. Iverson, and G. Georgiou, "Binding and enrichment of Escherichia coli spheroplasts expressing inner membrane tethered scFv antibodies on surface immobilized antigens, " Biotechnology and Bioengineering, vol. 98, no. 1, pp. 39-47, 2007.
77. J.-K. Qiu, S.-T. Jung, G. Georgiou, andH.-Y. Hang, "Enrichment of Escherichia coli spheroplasts displaying ScFv antibodies specific for antigens expressed on the human cell surface, " AppliedMicrobiology and Biotechnology, vol. 88, no. 6, pp. 1385-1391, 2010.
78. Y. Mazor, T. Van Blarcom, S. Carroll, and G. Georgiou, "Selection of full-length IgGs by tandem display on filamentous phage particles and Escherichia coli fluorescence-activated cell sorting screening, " FEBS Journal, vol. 277, no. 10, pp. 2291-2303, 2010.
79. J. Tomic, M. Mclaughlin, T. Hart, S. S. Sidhu, and J. Moffat, "Leveraging synthetic phage-antibody libraries for panning on the mammalian cell surface, " in Phage Display in Biotechnology and Drug Discovery, chapter 5, pp. 113-122, CRC Press, 2nd edition, 2015.
80. J. M. Watters, P. Telleman, and R. P. Junghans, "An optimized method for cell-based phage display panning, " Immunotechnology, vol. 3, no. 1, pp. 21-29, 1997.
81. M. J. McGuire, S. Li, and K. C. Brown, "Biopanning of phage displayed peptide libraries for the isolation of cell-specific ligands, " Methods in Molecular Biology, vol. 504, pp. 291-321, 2009.
82. J. J. Rice, A. Schohn, P. H. Bessette, K. T. Boulware, and P. S. Daugherty, "Bacterial display using circularly permuted outer membrane protein OmpX yields high affinity peptide ligands, " Protein Science, vol. 15, no. 4, pp. 825-836, 2006.
83. S. Takahashi, H. Mok, M. B. Parrott et al. , "Selection of chronic lymphocytic leukemia binding peptides, " Cancer Research, vol. 63, no. 17, pp. 5213-5217, 2003.
84. D. L. Siegel, T. Y. Chang, S. L. Russell, and V. Y. Bunya, "Isolation of cell surface-specific humanmonoclonal antibodies using phage display and magnetically-activated cell sorting: applications in immunohematology, " Journal of Immunological Methods, vol. 206, no. 1-2, pp. 73-85, 1997.
85. K. Y. Dane, L. A. Chan, J. J. Rice, and P. S. Daugherty, "Isolation of cell specific peptide ligands using fluorescent bacterial display libraries, " Journal of Immunological Methods, vol. 309, no. 1-2, pp. 120-129, 2006.
86. M. J. Feldhaus, R. W. Siegel, L. K. Opresko et al. , "Flowcytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library, " Nature Biotechnology, vol. 21, no. 2, pp. 163-170, 2003.
87. T. Keller, R. Kalt, I. Raab et al. , "Selection of scFv antibody fragments binding to human blood versus lymphatic endothelial surface antigens by direct cell phage display, " PLoS ONE, vol. 10, no. 5, Article ID e0127169, 2015.
88. L. R. H. Krumpe, A. J. Atkinson, G. W. Smythers et al. , "T7 lytic phage-displayed peptide libraries exhibit less sequence bias than M13 filamentous phage-displayed peptide libraries, " Proteomics, vol. 6, no. 15, pp. 4210-4222, 2006.
89. M. J. McGuire, K. N. Samli, Y.-C. Chang, and K. C. Brown, "Novel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomas, " Experimental Hematology, vol. 34, no. 4, pp. 443-452, 2006.
90. D.-K. Chang, C.-T. Lin, C.-H. Wu, and H.-C. Wu, "A novel peptide enhances therapeutic efficacy of liposomal anti-cancer drugs in mice models of human lung cancer, " PLoS ONE, vol. 4, no. 1, Article ID e4171, 2009.
91. G. S. Shukla and D. N. Krag, "Cancer cell-specific internalizing ligands from phage displayed β-lactamase-peptide fusion libraries, " Protein Engineering, Design and Selection, vol. 23, no. 6, pp. 431-440, 2010.
92. G. Abbineni, S. Modali, B. Safiejko-Mroczka, V. A. Petrenko, and C. Mao, "Evolutionary selection of new breast cancer celltargeting peptides and phages with the cell-targeting peptides fully displayed on the major coat and their effects on actin dynamics during cell internalization, "Molecular Pharmaceutics, vol. 7, no. 5, pp. 1629-1642, 2010.
93. S. Zitzmann, S. Krmer, W. Mier et al. , "Identification and evaluation of a new tumor cell-binding peptide, FROP-1, " Journal of Nuclear Medicine, vol. 48, no. 6, pp. 965-972, 2007.
94. K. A. Kelly and D. A. Jones, "Isolation of a colon tumor specific binding peptide using phage display selection, " Neoplasia, vol. 5, no. 5, pp. 437-444, 2003.
95. V. I. Romanov, D. B. Durand, and V. A. Petrenko, Phage display selection of peptides that affect prostate carcinoma cells attachment and invasion, Prostate, vol. 47, no. 4, pp. 239251, 2001.
96. P. K. Jayanna, D. Bedi, P. Deinnocentes, R. C. Bird, and V. A. Petrenko, "Landscape phage ligands for PC3 prostate carcinoma cells, " Protein Engineering, Design and Selection, vol. 23, no. 6, pp. 423-430, 2010.
97. J. Wang, Y. Liu, T. Teesalu et al. , "Selection of phage-displayed peptides on live adherent cells in microfluidic channels, " Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 17, pp. 6909-6914, 2011.
98. B. Liu, F. Conrad, M. R. Cooperberg, D. B. Kirpotin, and J. D. Marks, "Mapping tumor epitope space by direct selection of single-chain Fv antibody libraries on prostate cancer cells, " Cancer Research, vol. 64, no. 2, pp. 704-710, 2004.
99. F. Conrad, X. Zhu, X. Zhang et al. , "Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion, " Journal of Molecular Medicine, vol. 87, no. 5, pp. 507-514, 2009.
100. J.-M. Kupsch, N. H. Tidman, N. V. Kang et al. , "Isolation of human tumor-specific antibodies by selection of an antibody phage library on melanoma cells, " Clinical Cancer Research, vol. 5, no. 4, pp. 925-931, 1999.
101. B. Yu, M. Ni, W. H. Li et al. , "Human scFv antibody fragments specific for hepatocellular carcinoma selected from a phage display library, " World Journal of Gastroenterology, vol. 11, no. 26, pp. 3985-3989, 2005.
102. C. G. Jakobsen, N. Rasmussen, A.-V. Laenkholm, and H. J. Ditzel, "Phage display derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78, " Cancer Research, vol. 67, no. 19, pp. 9507-9517, 2007.
103. R. Willemsen, P. Chames, E. Schooten, J. W. Gratama, and R. Debets, "Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy, " Cytometry Part A, vol. 73, no. 11, pp. 1093-1099, 2008.
104. M. Figini, L. Obici, D. Mezzanzanica et al. , "Panning phage antibody libraries on cells: isolation of human Fab fragments against ovarian carcinoma using guided selection, " Cancer Research, vol. 58, no. 5, pp. 991-996, 1998.
105. D. A. Daniels, H. Chen, B. J. Hicke, K. M. Swiderek, and L. Gold, "A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment, " Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 26, pp. 15416-15421, 2003.
106. M. V. Berezovski, M. Lechmann, M. U. Musheev, T. W. Mak, and S. N. Krylov, "Aptamer-facilitated biomarker discovery (AptaBiD), " Journal of the American Chemical Society, vol. 130, no. 28, pp. 9137-9143, 2008.
107. L. T. Cherney, N. M. Obrecht, and S. N. Krylov, "Theoretical modeling of masking DNA application in aptamer-facilitated biomarker discovery, " Analytical Chemistry, vol. 85, no. 8, pp. 4157-4164, 2013.
108. I. M. Thompson, C. Chi, D. P. Ankerst et al. , "Effectoffinasteride on the sensitivity of PSA for detecting prostate cancer, " Journal of the National Cancer Institute, vol. 98, no. 16, pp. 1128-1133, 2006.
109. K. Kelly, H. Alencar, M. Funovics, U. Mahmood, and R. Weissleder, "Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide, " Cancer Research, vol. 64, no. 17, pp. 6247-6251, 2004.
110. S. Zitzmann, W. Mier, A. Schad et al. , "Anewprostate carcinoma binding peptide (DUP-1) for tumor imaging and therapy, " Clinical Cancer Research, vol. 11, no. 1, pp. 139-146, 2005.
111. D. M. Goldenberg, H. Goldenberg, R. M. Sharkey et al. , "Clinical studies of cancer radioimmunodetection with carcinoembryonic antigen monoclonal antibody fragments labeled with 123I or 99mTc, " Cancer Research, vol. 50, pp. 909s-921s, 1990.
112. J. De Vos, N. Devoogdt, T. Lahoutte, and S. Muyldermans, "Camelid single-domain antibody-fragment engineering for (pre) clinical in vivo molecular imaging applications: adjusting the bullet to its target, " Expert Opinion on Biological Therapy, vol. 13, no. 8, pp. 1149-1160, 2013.
113. P. P. Monnier, R. J. Vigouroux, and N. G. Tassew, "In vivo applications of single chain Fv (variable domain) (scFv) fragments, " Antibodies, vol. 2, no. 2, pp. 193-208, 2013.
114. O. H. Brekke and I. Sandlie, "Therapeutic antibodies for human diseases at the dawn of the twenty-first century, " Nature Reviews Drug Discovery, vol. 2, no. 1, pp. 52-62, 2003.
115. R. C. Ladner, A. K. Sato, J. Gorzelany, and M. De Souza, "Phage display-derived peptides as therapeutic alternatives to antibodies, " Drug Discovery Today, vol. 9, no. 12, pp. 525-529, 2004.
116. P. C. F. Oyston, M. A. Fox, S. J. Richards, and G. C. Clark, "Novel peptide therapeutics for treatment of infections, " Journal of Medical Microbiology, vol. 58, no. 8, pp. 977-987, 2009.
117. S. K. Tiwari and R. K. Chaturvedi, "Peptide therapeutics in neurodegenerative disorders, " Current Medicinal Chemistry, vol. 21, no. 23, pp. 2610-2631, 2014.
118. M. Vally, S. Seenu, and S. Pillarisetti, "Emerging peptide therapeutics for inflammatory diseases, " Current Pharmaceutical Biotechnology, vol. 7, no. 4, pp. 241-246, 2006.
119. M. J. Miller, K. C. Foy, and P. Kaumaya, "Cancer immunotherapy: present status, future perspective, and a new paradigm of peptide immunotherapeutics, " Discovery Medicine, vol. 15, no. 82, pp. 166-176, 2013.
120. P. K. Smith, S. K. Shernan, J. C. Chen et al. , "Effects of C5 complement inhibitor pexelizumab on outcome in highrisk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials, " Journal of Thoracic and Cardiovascular Surgery, vol. 142, no. 1, pp. 89-98, 2011.
121. M. J. Evans, S. A. Rollins, D. W. Wolff et al. , "In vitro and in vivo inhibition of complement activity by a single-chain Fv fragment recognizing human C5, " Molecular Immunology, vol. 32, no. 16, pp. 1183-1195, 1995.
122. G.-M. Lin, "Pexelizumab, an anti-C5 complement antibody for primary coronary revascularization: a new insight from old versions, " Cardiovascular and Hematological Disorders-Drug Targets, vol. 11, no. 2, pp. 97-101, 2011.
123. J. C. K. Fitch, S. Rollins, L. Matis et al. , "Pharmacology and biological efficacy of a recombinant, humanized, single-chain antibody C5 complement inhibitor in patients undergoing coronary artery bypass graft surgery with cardiopulmonary bypass, " Circulation, vol. 100, no. 25, pp. 2499-2506, 1999.
124. W. Wels, I.-M. Harwerth, M. Mueller, B. Groner, and N. E. Hynes, "Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor, " Cancer Research, vol. 52, no. 22, pp. 6310-6317, 1992.
125. G. Von Minckwitz, S. Harder, S. Hvelmann et al. , "Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas, " Breast Cancer Research, vol. 7, no. 5, pp. R617-626, 2005.
126. G. K. Lam, M. Hopoate-Sitake, C. D. Adair et al. , "Digoxin antibody fragment, antigen binding (Fab), treatment of preeclampsia in women with endogenous digitalis-like factor: a secondary analysis of the DEEP Trial, " American Journal of Obstetrics and Gynecology, vol. 209, no. 2, pp. 119. e1-119. e6, 2013.
127. B. Frigerio, G. Fracasso, E. Luison et al. , "A single-chain fragment against prostate specificmembrane antigen as a tool to build theranostic reagents for prostate cancer, " European Journal of Cancer, vol. 49, no. 9, pp. 2223-2232, 2013.